Could a lower dose of a common antibiotic be safer and just as effective for a deadly pneumonia?
NCT ID NCT07690410
First seen Jul 08, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This study looks at whether a lower dose of the antibiotic TMP-SMX works as well as the standard dose for treating a serious lung infection called Pneumocystis pneumonia (PCP) in people who do not have HIV. The standard dose often causes side effects in more than half of patients. The trial will follow about 480 adults in hospitals to compare treatment failure rates and side effects between the two dosing strategies, without changing the care doctors normally provide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trimethoprim-sulfamethoxazole (TMP-SMX)
- What this could lead to
- If successful, a lower dose of TMP-SMX could become the standard treatment for non-HIV PCP, reducing severe side effects without compromising survival.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less definitive. The lower dose might also be less effective in some patients, and side effects remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS JIROVECII PNEUMONIA IN NON-HIV PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.